Humanigen Inc. [HGEN] Chief Scientific Officer makes an insider purchase of 545,488 shares worth 1.22 million.

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Humanigen Inc. shares valued at $1,215,347 were purchased by Chappell Dale on May 20. At $2.23 per share, Chappell Dale acquired 545,488 shares. The insider’s holdings grew to 8,675,081 shares worth approximately $1.39 million following the completion of this transaction.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Also, Chappell Dale purchased 323,808 shares, netting a total of over 707,844 in proceeds. Following the buying of shares at $2.19 each, the insider now holds 8,293,240 shares.

Before that, Chappell Dale had added 173,700 shares to its account. In a trade valued at $340,799, the Chief Scientific Officer bought Humanigen Inc. shares for $1.96 each. Upon closing the transaction, the insider’s holdings increased to 173,700 shares, worth approximately $1.29 million.

As published in a research note from ROTH Capital on July 13, 2022, Humanigen Inc. [HGEN] has been rated down from a Buy to a Neutral and the price target has been revised to $2 from $13. This represents a 92.0% premium over Wednesday’s closing price. Analysts at H.C. Wainwright downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in mid July. As of July 13, 2022, Cantor Fitzgerald has decreased its “an Overweight” rating to a “Neutral” for HGEN. Earlier on September 10, 2021, Jefferies downgraded its rating. Their new recommendation was “a Hold” for HGEN stock which previously was a “a Buy”.

Analyzing HGEN’s Price Performance

On Wednesday, Humanigen Inc. [NASDAQ: HGEN] plunged -8.98% to $0.16. The stock’s lowest price that day was $0.1612, but it reached a high of $0.181 in the same session. During the last five days, there has been a drop of approximately -24.46%. Over the course of the year, Humanigen Inc. shares have dropped approximately -95.64%. Shares of the company reached a 52-week high of $4.1050 on 03/21/22 and a 52-week low of $0.1612 on 09/21/22. A 50-day SMA is recorded $0.3284, while a 200-day SMA reached $2.1042. Nevertheless, trading volume fell to 4.08 million shares from 2.09 million shares the previous day.

Support And Resistance Levels for Humanigen Inc. (HGEN)

According to the 24-hour chart, there is a support level at 0.1552, which, if violated, would cause prices to drop to 0.1483. In the upper region, resistance lies at 0.1750. The next price resistance is at 0.1879. RSI (Relative Strength Index) is 24.69 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0297, which suggests the price will decrease in the coming days. Percent R is at 98.83%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Humanigen Inc. subject to short interest?

Stocks of Humanigen Inc. saw a sharp steep in short interest on Aug 30, 2022 dropping by -6.0 million shares to 4.0 million. Data from Yahoo Finance shows that the short interest on Jul 28, 2022 was 10.0 million shares. A decline of -150.0% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.49 of the overall float, the days-to-cover ratio (short ratio) decline to 0.49.

Which companies own the most shares of Humanigen Inc. (HGEN)?

According to Black Horse Capital Management LL filings, the company currently owns 12,134,287 shares, which is about 11.71% of the total HGEN shares outstanding. A total of 378,174 shares of Humanigen Inc. were bought by Cowen & Co. LLC during the quarter, and -2,148,037 were sold by BlackRock Fund Advisors. In its current portfolio, Marshall Wace LLP holds 608,736 shares valued at $0.14 million.

In terms of Humanigen Inc. share price expectations, FactSet research, analysts set an average price target of $9.88 in the next 12 months, up nearly 2955.56% from the previous closing price of $0.18. Analysts anticipate Humanigen Inc. stock to reach $28.00 by 2022, with the lowest price target being $0.50. In spite of this, 3 analysts ranked Humanigen Inc. stock as an Underweight at the end of 2022. On September 09, 2021, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $28.

LEAVE A REPLY

Please enter your comment!
Please enter your name here